source
- Claris Bio secures $118 million to launch pivotal eye-drop trials next yearClaris Bio announced a financing round that raised $118 million to move its investigational eye‑drop therapy forward. The capital will fund two pivotal Phase 3 studies slated to start next year, f…
- GSK launches three-year cost-cutting plan as new CEO targets R&D efficiencyGSK announced a three-year restructuring program designed to cut costs and sharpen focus on its advanced assets. The plan was presented by CEO Luke Miels, who has been in the role for just over si…